Alzheimer's Disease Study Remote Administration Date Published: May 08, 2020 Whitepaper Alzheimer’s Disease studies generally have low success rates so when the COVID-19 pandemic required clinical trials to change to remote administration models, it became more critical than ever to maximize the quantity and quality of data in these studies. Signant Health’s David Miller outlines considerations for optimizing the quality and reliability of remote outcomes assessment data, including: Validating scales for audio and/or video administrationConfirming if input is needed from patient and/or caregiverEnsuring all participants understand their rolesConsidering study drug administrationMeeting site location needsRespecting the patient’s discomfort with an at-home administer during COVID-19 Download Now Share: LinkedInTweet Recommended Resources The EMA Recommendation Paper on Decentralized Elements in Clinical Trials: An Overview Read Our White Paper Whitepaper Optimal COA Measurement Strategy in Modern Oncology Trials Read Our White Paper Whitepaper Site Perspectives on BYOD ePRO Use Download Whitepaper